Increased Risk for Inflammatory Arthritis in Patients With Newly Diagnosed Hidradenitis Suppurativa
Researchers assessed risk for inflammatory arthritis in patients with newly diagnosed hidradenitis suppurativa.
Psoriatic Arthritis
Psoriasis, Psoriatic Arthritis Associated With Inflammatory Bowel Disease and Other Gastrointestinal Illnesses
Researchers evaluated the association of psoriasis and psoriatic arthritis with inflammatory bowel disease and other gastrointestinal illnesses.
Steroid Injections Improve Pain and Functionality Measures in Hand Psoriatic Dactylitis
Researchers assessed the effectiveness of steroid injections vs systemic treatment on dactylitis in patients with psoriatic arthritis.
Upadacitinib Application for Active Psoriatic Arthritis Submitted for Review
AbbVie has submitted an application to the FDA for review of upadacitinib in the treatment of active psoriatic arthritis (PsA) in adults.
Do TNFis Reduce the Risk for Progression to PsA in Patients With Psoriasis?
Researchers evaluated the use of TNFis vs methotrexate in reducing the risk for progression to psoriatic arthritis in patients with psoriasis.
Integrated Analysis Shows Long-Term Safety, Tolerability of Ixekizumab in Psoriasis, PsA, and axSpA
Researchers evaluated the long-term safety and tolerability of ixekizumab in adults with psoriasis, psoriatic arthritis and axial spondyloarthritis.
![There are no uniform guidelines regarding DMARD tapering. EULAR guidelines suggest RA pharmacotherapy should be de-escalated in the following order: glucocorticoids, biologic DMARDs, and, finally, conventional DMARDs, with each treatment stopping completely before de-escalation of the next agent in the sequence.[4] Numerous DMARD dose-tapering protocols have been studied, including immediate discontinuation of treatment. When the goal is to withdraw treatment, the ACR recommends an initial dose-tapering phase to enable better monitoring of patient response and candidacy for discontinuation.[5] The ACR also strongly encourages patient involvement in decisions regarding their individual DMARD tapering protocol.](https://1fxghyessyy2gaob23ygwzph-wpengine.netdna-ssl.com/wp-content/uploads/sites/18/2019/01/syringedrugsts53728911801_1026507-544x306.jpg)
Literature Review of 2019 EULAR Recommendations for PsA Management Indicates Efficacy, Safety of Pharmacologic Treatment
Researchers performed a review of the efficacy and safety of disease-modifying antirheumatic drugs in psoriatic arthritis.
Apremilast Improves Psoriatic Disease and Cardiometabolic Markers
A novel study assesses the safety and efficacy of apremilast in patients with psoriasis and evaluates the treatment as a metabolic modulator.
Guselkumab Demonstrates Favorable Benefit-Risk Profile in Biologic-Naive Patients With Active Psoriatic Arthritis
In both the DISCOVER-1 and DISCOVER-2 trials, the researchers assessed guselkumab treatment in biologic-naive patients with active psoriatic arthritis.
TNFi Combination Therapy vs Monotherapy Improves Drug Survival in Psoriatic Arthritis
Researchers compared the effectiveness of tumor necrosis factor inhibitor combination therapy vs monotherapy in psoriatic arthritis.
-
Loading...
-
Loading...
Next post in Spondyloarthritis
